CD274 and neoplasm: Assessment of PD-L1 expression in tumor tissue has been widely used to determine the therapeutic approach of either a single-agent anti-PD-1 inhibitor or the combination of platinum doublet with anti-PD-1 for patients with tumor PD-L1 expression ≥50% or <50%, respectively (4, 8).